BCL-201 (S55746)
$135.00 – $595.00
- Details & Specifications
- References
- More Offers
Description
Background Information:
BCL-201 (S55746, Servier-1) is an orally bioavailable, potent and selective BH3-mimetic inhibitor of BCL-2 with a Ki of 1.3 nM, highly selective over BCL-XL (70- 400 fold), and no significant binding to MCL-1 and BFL-1 (BCL2A1/A1). S55746 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo, S55746 induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, S55746 administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior (ref.1).
Reference:
1. P. Casara, et al, S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth, Oncotarget. 2018; 9:20075-20088.
APIM050284: BCL-201 (S55746)
CAS No.: 1448525-91-4.
Molecular Formula: C43H42N4O6.
Molecular Weight: 710.8.
Purity: >99% Chemically and Enantiomerically Pure by achiral and chiral HPLCs.
QC: Achiral and Chiral HPLCs, MS, NMR, and Elemental Analysis.
Solubility: Refer to Certificate of Analysis.
Storage: Refer to Certificate of Analysis.
